MorphoSys AG (MOR) Given Consensus Rating of “Buy” by Brokerages
MorphoSys AG (ETR:MOR) has received a consensus rating of “Buy” from the six analysts that are covering the firm, Marketbeat reports. Three equities research analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is €67.00 ($76.14).
A number of equities research analysts recently weighed in on the stock. J P Morgan Chase & Co reaffirmed a “neutral” rating on shares of MorphoSys AG in a report on Monday. Independent Research GmbH set a €77.00 ($87.50) price objective on shares of MorphoSys AG and gave the company a “buy” rating in a research report on Monday. Goldman Sachs Group, Inc. (The) set a €55.00 ($62.50) price objective on shares of MorphoSys AG and gave the company a “neutral” rating in a research report on Monday. HSBC Holdings plc set a €59.00 ($67.05) price objective on shares of MorphoSys AG and gave the company a “neutral” rating in a research report on Friday. Finally, Commerzbank Ag set a €76.00 ($86.36) price objective on shares of MorphoSys AG and gave the company a “buy” rating in a research report on Friday.
COPYRIGHT VIOLATION WARNING: “MorphoSys AG (MOR) Given Consensus Rating of “Buy” by Brokerages” was reported by American Banking News and is the property of of American Banking News. If you are reading this story on another publication, it was stolen and republished in violation of international copyright legislation. The correct version of this story can be viewed at https://www.americanbankingnews.com/2017/07/17/morphosys-ag-mor-given-consensus-rating-of-buy-by-brokerages.html.
Shares of MorphoSys AG (ETR:MOR) traded up 0.15% during trading on Monday, reaching €67.00. 5,962 shares of the company’s stock traded hands. The stock has a 50-day moving average of €62.72 and a 200-day moving average of €54.66. The company’s market capitalization is €1.93 billion. MorphoSys AG has a 1-year low of €35.72 and a 1-year high of €68.33.
MorphoSys AG Company Profile
MorphoSys AG develops and commercializes antibodies for therapeutic applications. The Company develops drugs using its own research and development, as well as in cooperation with pharmaceutical and biotechnology partners. The Company’s operating segments include Proprietary Development and Partnered Discovery.
Receive News & Ratings for MorphoSys AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys AG and related companies with MarketBeat.com's FREE daily email newsletter.